苯丁酸鈉作用機制 - Medchemexpress - MCE中國_第1頁
苯丁酸鈉作用機制 - Medchemexpress - MCE中國_第2頁
苯丁酸鈉作用機制 - Medchemexpress - MCE中國_第3頁
全文預覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)

文檔簡介

1、Product Data SheetBenzenebutyric acid sodiumCat. No.: HY-15654CAS No.: 1716-12-7分式: CHNaO分量: 186.18作靶點: HDAC; Autophagy; Apoptosis作通路: Cell Cycle/DNA Damage; Epigenetics; Autophagy; Apoptosis儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 33.33 mg/mL (179.02 mM

2、; Need ultrasonic)H2O : 23.5 mg/mL (126.22 mM; Need ultrasonic and warming)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 5.3711 mL 26.8557 mL 53.7115 mL5 mM 1.0742 mL 5.3711 mL 10.7423 mL10 mM 0.5371 mL 2.6856 mL 5.3711 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。儲備液的保存式和期限:-80C, 6 mo

3、nths; -20C, 1 month。-80C 儲存時,請在 6 個內(nèi)使,-20C 儲存時,請在 1 個內(nèi)使。體內(nèi)實驗請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍浮R韵氯芙獍付颊埾劝凑?In Vitro 式配制澄清的儲備液,再依次添加助溶劑:為保證實驗結(jié)果的可靠性,澄 的儲備液可以根據(jù)儲存條件,適當保存;體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當天使; 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility:

4、2.5 mg/mL (13.43 mM); Clear solution此案可獲得 2.5 mg/mL (13.43 mM,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中,混合均勻;向上述體系中加50 L Tween-80,混合均勻;然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (13.43 mM); Clear solutionPage 1 of 2 www

5、.MedChemE此案可獲得 2.5 mg/mL (13.43 mM,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中,混合均勻。3. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (13.43 mM); Clear solution此案可獲得 2.5 mg/mL (13.43 mM,飽和度未知) 的澄 溶液,此案不適于實驗周 期在半個以上的實驗。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DM

6、SO 儲備液加到 900 L 油中,混合均勻。BIOLOGICAL ACTIVITY物活性 Benzenebutyric acid sodium (4-Phenylbutyric acid sodium)劑,可于癌癥和感染等疾病的研究。種組蛋去?;?(HDAC) 和內(nèi)質(zhì)應激 (ERS) 抑制IC & Target HDAC體外研究 Benzenebutyric acid sodium (Sodium phenylbutyrate) is an inhibitor of HDAC, inhibits the growth of NSCLC Cell Linesat 2 mM. Benzeneb

7、utyric acid sodium in combination with ciglitizone results in enhanced growth arrest of cancer cells1. Benzenebutyric acid sodium (Sodium phenylbutyrate; 0-5 mM) inhibits ASFV infection in a dose-dependentmanner. Benzenebutyric acid sodium also inhibits the ASFV late protein synthesis and disrupts t

8、he virus-inducedH3K9/K14 hypoacetylation status. Benzenebutyric acid sodium and Enrofloxacin act synergistically to abolish ASFVreplication2. Addition of Bafilomycin A1 results in accumulation of LC3II, whereas Benzenebutyric acid (4-PBA)substantially reduces this accumulation. LPS decreases the lev

9、el of p62, whereas Benzenebutyric acid reverses thisdecrease upon LPS stimulation for 48 h. The percentage of cells with LPS-induced AVOs is increased at 48 h, whereasBenzenebutyric acid significantly reduces this percentage. Specifically, the percentage of cells with AVOs decreasesfrom 61.6% to 53.

10、1% upon Benzenebutyric acid treatment, supporting that Benzenebutyric acid inhibits LPS-inducedautophagy. As a positive control for autophagy inhibition, bafilomycin A1 is used. The percentage of cells with LPS-induced AVOs is reduced by bafilomycin A1 treatment. The decreased OC area and fusion ind

11、ex observed afterBenzenebutyric acid treatment are not observed with knockdown of ATG7. Inhibition of NF-B using BAY 11-7082and JSH23 reduce the LC3 II level upon LPS stimulation and completely abolish the inhibitory effect of Benzenebutyricacid on LPS-induced effects3.體內(nèi)研究 LPS induces significant b

12、one loss and decreases bone mineral density (BMD), bone volume (BV/TV), and trabecularthickness (Tb. Th) compared with PBS alone, whereas trabecular space (Tb. Sp.) is increased. Benzenebutyric acidsodium (Sodium phenylbutyrate) attenuates LPS-induced bone loss. Treatment with Benzenebutyric acid so

13、diumincreases BMD, BV/TV, and Tb. Th. compared with LPS alone, in addition to decreasing the enlargement of Tb. Sp., butno change is observed when mice are treated with Benzenebutyric acid sodium alone. OC.S/BS as assessed by TRAPstaining is also significantly reduced when Benzenebutyric acid sodium

14、 is administered to LPS-treated mice. However,OC.N/BS tends to decrease, although not with statistical significance, when mice are treated with Benzenebutyric acidsodium and LPS. These results indicate that the effect of Benzenebutyric acid sodium on OC from LPS-treated mice isto reduce its size rat

15、her than number. Consistent with these findings, a marker of bone resorption in vivo, serum CTX-1 which is elevated by LPS treatment is decreased when Benzenebutyric acid sodium administered to LPS-injectedmice. However, co-treatment with Benzenebutyric acid sodium do not significantly affect the le

16、vels of serum ALP andosteocalcin, 2 markers of bone formation in vivo, compared with LPS alone. Benzenebutyric acid sodium also reducesthe LPS-induced rise in serum MCP-1, indicating that Benzenebutyric acid sodium decreases systemic inflammationinduced by LPS3.PROTOCOLPage 2 of 3 www.MedChemECell A

17、ssay 1 Briefly, viable cells, as judged by trypan blue dye exclusion, are seeded at a density of 4 104 cells/mL in 60-mmdishes in RPMI 1640 with 10% fetal bovine serum and 0.35% agarose on a base layer of 0.7% agarose. DMSO, TSA,or PB is added to both bottom and top agarose layers. Assays are perfor

18、med in triplicate on at least three separateoccasions, and colonies are counted at 10-14 days1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice3Administration 3 Female 10-week-old C57BL/6J mice are housed in the pathogen-free animal facility

19、of IRC. Animals arerandomized into the following 4 groups: vehicle control (n=5), vehicle+Benzenebutyric acid (n=6), LPS (n=6), andLPS+Benzenebutyric acid (n=6). Mice are treated with LPS in 200 L phosphate-buffered saline (PBS) once a week(5 mg/kg, i.p.) for 3 weeks. Benzenebutyric acid solution is

20、 prepared by titrating equimolecular amounts ofBenzenebutyric acid and sodium hydroxide to reach pH 7.4; mice are injected daily intraperitoneally in 200 L PBS(or with PBS as a vehicle) at a dose of 240 mg/kg for 3 weeks. Mice are sacrificed by CO2 asphyxiation. Todetermine the bone mineral density

21、(BMD) and microarchitecture of the long bone, the right femur is scanned.Scans are performed with an effective detector pixel size of 6.9 m and a threshold of 77-255 mg/cc. Trabecularbone is analyzed in a region 1.6 mm in length and located 0.1 mm below the distal femur growth plate3.MCE has not ind

22、ependently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻 Cell Death Dis. 2020 Apr 24;11(4):279. Cell Death Dis. 2018 Nov 16;9(12):1143. J Mol Med (Berl). 2019 Aug;97(8):1183-1193. Food Chem Toxicol. 2020 Apr 10:111329. Food Chem Toxicol. 2019 Dec 28;136:111080.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Chang TH, et al. Enhanced growth inhibition by combination differentiation therapy with ligands of perox

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論